Insider Shareholders with Direct Ownership of Horizon Therapeutics Public LTD CO (HZNP)
This section provides a comprehensive overview of the insiders with direct ownership of Horizon Therapeutics Public LTD CO (HZNP). You can find detailed information about the size and nature of each insider's ownership stake, as well as the latest updates on their holdings.
Horizon Therapeutics Public Ltd Co Insider List
| Insider | Adquired | Disposed | Held | # of Trades | Last Transaction |
|---|---|---|---|---|---|
|
Timothy P Walbert
Chairman, President and CEO |
4,453,954 | 4,639,487 | 616,493 $0 | 109 |
Jan 05, 2023
Reduced 13.65%
|
|
Virinder Nohria
Director |
0 | 1,764,130 | 189,836 $0 | 2 |
Jun 15, 2016
Reduced 11.64%
|
|
Barry Moze
EVP, Chief Admin. Officer |
634,414 | 506,950 | 138,174 $0 | 53 |
Jan 05, 2022
Reduced 26.51%
|
|
Thomas Watkins
Director |
91,236 | 110,447 | 110,447 $0 | 4 |
Sep 29, 2023
Added 16.18%
|
|
Shao Lee Lin
EVP, Head of R&D and CSO |
195,922 | 87,303 | 109,668 $0 | 12 |
Jan 21, 2020
Reduced 2.42%
|
|
Vikram Karnani
EVP & President, International |
306,805 | 230,121 | 104,165 $0 | 35 |
Feb 22, 2021
Reduced 0.62%
|
|
Gino Santini
Director |
82,800 | 112,959 | 100,959 $0 | 6 |
Oct 02, 2023
Added 18.61%
|
|
Jeff Kent
Officer |
150,916 | 165,759 | 83,586 $0 | 27 |
May 11, 2021
Added 13.09%
|
|
Irina Konstantinovsky
EVP, Chief Human Resources Off |
333,424 | 253,578 | 81,677 $0 | 31 |
Feb 22, 2021
Reduced 0.58%
|
|
Brian K Beeler
EVP, General Counsel |
416,548 | 386,109 | 62,775 $0 | 49 |
Sep 17, 2021
Reduced 30.95%
|
|
Geoffrey M. Curtis
EVP, Corporate Affairs, CCO |
279,904 | 242,322 | 52,675 $0 | 34 |
Apr 01, 2021
Reduced 57.32%
|
|
Daniel A. Camardo
EVP and President, U.S. |
53,415 | 32,093 | 51,181 $0 | 11 |
Apr 05, 2021
Added 0.98%
|
|
Miles W Mc Hugh
Sr VP & Princ. Acctg Officer |
317,968 | 285,751 | 46,635 $0 | 49 |
Jan 05, 2022
Reduced 14.92%
|
|
Jeff Himawan
Director |
36,074 | 56,528 | 44,546 $0 | 6 |
Sep 26, 2023
Added 41.93%
|
|
George P Hampton
EVP, Primary Care Bus. Unit |
58,500 | 20,602 | 41,473 $0 | 10 |
Apr 01, 2018
Reduced 6.23%
|
|
Timothy J. Ackerman
SVP, Commercial Operations |
31,675 | 3,733 | 41,129 $0 | 6 |
Jan 10, 2017
Added 4.23%
|
|
Michael G Grey
Director |
59,708 | 75,156 | 39,361 $0 | 15 |
Sep 28, 2023
Added 33.69%
|
|
Jeffrey W Sherman
EVP and Chief Medical Officer |
642,417 | 550,328 | 36,171 $0 | 65 |
Jan 11, 2023
Reduced 8.52%
|
|
James Samuel Shannon
Director |
47,995 | 67,267 | 33,156 $0 | 10 |
Sep 29, 2023
Added 26.33%
|
|
William F Daniel
Director |
23,913 | 53,794 | 31,915 $0 | 5 |
Apr 28, 2023
Reduced 5.56%
|
|
Robert Carey
EVP, Chief Business Officer |
386,170 | 184,495 | 17,267 $0 | 21 |
Mar 23, 2019
Reduced 44.3%
|
|
Pascale Witz
Director |
3,913 | 27,551 | 16,323 $0 | 3 |
Apr 28, 2023
Reduced 10.32%
|
|
John J Kody
EVP, Chief Commercial Officer |
18,975 | 6,209 | 12,766 $0 | 2 |
Nov 24, 2015
Reduced 32.72%
|
|
John B Thomas
EVP, Corporate Strategy and IR |
9,375 | 2,916 | 7,620 $0 | 2 |
May 06, 2016
Reduced 27.68%
|
|
Sean M. Clayton
EVP, General Counsel |
14,129 | 14,687 | 7,376 $0 | 3 |
Mar 01, 2023
Reduced 48.81%
|
|
David Happel
EVP, Commercial Dev & Strategy |
7,953 | 4,150 | 5,089 $0 | 2 |
Oct 25, 2017
Reduced 44.92%
|
|
Eric Mosbrooker
SVP, Orphan Business Unit |
4,435 | 2,315 | 3,585 $0 | 2 |
Nov 01, 2017
Reduced 39.24%
|
|
Susan Mahony
Director |
3,913 | 11,224 | 2,034 $0 | 3 |
Apr 28, 2023
Reduced 48.02%
|
|
Paul W. Hoelscher
EVP, CFO |
1,288,469 | 1,297,643 | 1,049 $0 | 57 |
Apr 20, 2022
Reduced 95.36%
|
|
Andy Pasternak
EVP, Chief Strategy Officer |
270,165 | 272,452 | 0 $0 | 29 |
Oct 06, 2023
Reduced 100.0%
|
|
Elizabeth H.Z. Thompson
EVP, Research & Development |
45,131 | 60,771 | 0 $0 | 13 |
Oct 06, 2023
Reduced 100.0%
|
|
Michael A. Des Jardin
EVP, Technical Operations |
466,447 | 475,602 | 0 $0 | 57 |
Oct 06, 2023
Reduced 100.0%
|
|
Aaron Cox
EVP, Chief Financial Officer |
65,183 | 70,236 | 0 $0 | 6 |
Oct 06, 2023
Reduced 100.0%
|
|
Patrick Mc Ilvenny
Chief Accounting Officer |
7,973 | 11,021 | 0 $0 | 3 |
Oct 06, 2023
Reduced 100.0%
|